Objective:

To discuss the challenges in the adoption of companion diagnostics in routine clinical practice, including scientific, operational, behavioral, and reimbursement issues, and the role of pathologists in expanding access.

Approach:

Key Findings:

• Adoption of biomarkers can take 5 to 10 years due to the need for extensive validation, impacting timely patient care.
• Community hospitals face significant barriers in implementing NGS testing compared to academic centers, leading to treatment delays.
• Reimbursement processes are often lengthy and complex, hindering the adoption of precision diagnostics and affecting patient access.
• Limited access to advanced testing in lower-income countries exacerbates disparities in precision medicine, highlighting the need for global solutions.

Interpretation:

The slow adoption of companion diagnostics is multifaceted, involving scientific, operational, behavioral, and reimbursement challenges that must be addressed to improve patient outcomes and equity in healthcare.

Limitations:

• The article does not provide specific case studies or quantitative data to support claims, which could strengthen the argument.
• Focus is primarily on the US and Europe, with limited discussion on global disparities, which may overlook critical issues in other regions.

Conclusion:

To enhance access to precision medicine, diagnostics companies must innovate their approaches, focusing on practical solutions that integrate testing into routine care across various healthcare settings.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.